Brachial plexopathy following use of recombinant human BMP-2 for treatment of atrophic delayed union of the clavicle

John R. Matthews, David S. Margolis, Eileen Wu, Lisa M Truchan

Research output: Contribution to journalArticle

1 Scopus citations


Case: Although recombinant human bone morphogenetic protein-2 (rhBMP-2) is approved for treatment of open tibial fractures and anterior lumbar interbody fusion, off-label use has been associated with complications such as local inflammation, osteolysis, and dysphagia. This case report describes a patient treated with rhBMP-2 for an atrophic delayed union of a clavicular fracture who subsequently developed a profound motor and sensory brachial plexopathy. Conclusion: Use of rhBMP-2 near peripheral nerves may cause neuropathy. This should be considered prior to its use in surgical sites with peripheral nerves in proximity.

Original languageEnglish (US)
Article numbere81
JournalJBJS Case Connector
Issue number3
Publication statusPublished - Jul 8 2015


ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this